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Abstract
This paper proposes a new method of improved meta analysis to combine
relative risk for both homogeneous and heterogeneous set of studies. The stan-
dard meta analyses don’t give any conclusive result when the effects of het-
erogenous studies are combined. The proposed improved meta analysis uses
the predicted relative risk, and chi-square test to check the heterogeneity of
the effects. Confidence intervals for the relative risks obtained via improved
method concentrate more towards the value of the pooled estimate than that of
the standard meta analysis. Exclusion of identified studies with outliers from
the analysis brings the results of the remaining studies closer to the pooled
estimate. An illustration shows that the new method improves the results and
provide conclusive estimate of the relative risk.
Key Words: Relative risk, predicted relative risk, odds ratio, chi-square test, stan-
dard meta analysis.
1 Introduction
Meta analysis is a statistical procedure that integrates the results of several inde-
pendent studies to be combinable. It usually integrates and summarizes the findings
from many clinical studies of treatments because an individual study of a particular
treatment may not be as conclusive as several studies put together. A meta analy-
sis also helps to gain greater objectivity and precision by including all the available
evidence from randomized trials that pertain to the issue [1]. Since the 1980’s there
has been an upsurge in the application of meta analysis in medical research. Over
the same period there have been great strides in the development and refinement of
the associated statistical methodology. These developments have mainly been due to
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greater emphasis on evidence-based medicine and the need for reliable summaries of
the vast and expanding volume of clinical research.
If there exists homogeneity in the treatment effects among the trials considered,
standard meta analysis provides conclusive results. However the method is not useful
for integrating treatment effects which are heterogenous in character. The most
obvious cause of the heterogeneity in the treatment effects relates to the ages of the
participants, or more particularly the average age of experiencing the event during
follow up, since it is well known that the relative risk associated with a particular
disease with a given treatment declines with advancing age [2]. Other factors causing
non-homogeneous treatment effects are environment in which the trials are conducted.
Despite the laudable attempts to achieve objectivity in reviewing scientific data,
considerable subjective judgment is necessary in carrying out meta analyses. These
judgments include those about which studies are “relevant” and which studies are
methodologically sound enough to be included, as well as the issue of whether and
how to investigate sources of heterogeneity [3]. Saleh et al.[4] introduced an improved
meta analysis for handling studies having statistically heterogeneous treatment effects
and achieved reliable (minimum mean square sense) quantitative conclusions.
Most of the meta analyses are performed for combining odds ratios. Odds ratio
is the ratio of odds of treatment group to control group. Such studies consider the
odds rather than the actual risks for the treatment and placebo groups, and hence
it is not necessarily a better estimate of the treatment effects. In mathematical
epidemiology, relative risk is a ratio of the probability of the event occurring in the
exposed group versus the control (non-exposed) group. Relative risk is used frequently
in the statistical analysis of binary outcomes where the outcomes of interest has
relatively low probability. It is thus often more suited to analyze clinical trial data,
that are used to compare the risk of developing a disease in people not receiving
the new medical treatment versus people who are receiving an established treatment.
The relative risk is easily interpretable than other parameters used in medical science.
While comparing a new treatment to the control, if a relative risk is less than one, then
it would indicate an improvement on the new treatment; whereas a ratio greater than
one would imply the new treatment was less effective than any treatment received by
the control group.
In this paper we consider both homogeneous and heterogenous sets of treatments
and perform standard meta analyses for relative risks. We estimate relative risks,
weights and construct confidence intervals for individual studies as well as combining
them. We test the heterogeneity of trials for both the cases and check the validity
of the meta analyses. We then perform improved meta analysis of relative risk for
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heterogeneous set of studies where usual meta analysis fails to provide conclusive
result. Improve meta analysis combines the estimated relative risk with the value
of the test statistic to get the treatment effect. This method it is expected to yield
better estimate of the treatment effect than conventional meta analyses.
2 Standard meta analysis
Standard meta analysis is performed for the data produced by randomised control
trails (RCT). The idea is to integrate or combine studies or groups which are more or
less homogenous with respect to the parameter to be estimated to make conclusion
on the effectiveness any new drug or medical procedure.
2.1 Methodology
Outcome variables in terms of odds ratio or relative risk or weighted mean difference
are commonly used in meta analysis. Here we consider meta analysis based on the
relative risk. From the data we first estimate the relative risks and weights of indi-
vidual studies. The weight of a study is the inverse of the variance of the respective
study, and the combined effect is calculated as a weighted average of the relative risk
from individual studies. Weighted geometric mean is the appropriate estimate here.
Let for the ith study, the number of respondents for treatment and control groups
with success and failure criteria be given as Table 1.
Table 1 Number of individuals for different subgroups.
Success Failure Total
Treatment x1i n1i-x1i n1i
Control x2i n2i- x2i n2i
The different steps for conducting meta analysis of relative risk is as follows:
• Calculate the relative risk of the treatment and log relative risk. For the ith
study, the estimated risk for the treatment and control groups are Rti =
x1i
n1i
and Rci =
x2i
n2i
respectively. Then the estimated relative risk for ith study is
θˆi = RR =
Rti
Rci
.
The corresponding log relative risk is defined as the natural logarithm of the
estimated relative risk. Thus for the ith study the log RR becomes
lˆi = ln(θˆi).
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• Calculate the variance of log relative risk of the treatment. For the ith study
the variance of the log RR is defined as
σˆ2i = Var[ln(θˆi)] =
1
x1i
− 1
n1i
+
1
x2i
− 1
n2i
.
• Calculate the weights of the ith study by taking the inverse of the variance of
the log RR as
wi =
1
Var[ln ˆ(θ)i]
.
• Calculate the estimated pooled log relative risk of the treatment by taking
weighted geometric mean of the individual log relative risks from all the studies
from all the studies . Thus the estimated pooled log RR becomes
θˆ = exp
[∑
wi × ln(θˆi)∑
wi
]
.
• Calculate the variance of the estimated Pooled log RR as the weighted average
of variances of individual studies as
σ2(θˆ) =
∑
w2i × σˆ2i
n2
.
• Calculation of confidence intervals for individual studies: The (1 − α)100%
confidence interval for the log RR [5] is obtained as
lˆi± zα/2 ×
√
w−1i .
Accordingly the (1− α)100% confidence interval for the RR is obtained as
exp[lˆi± zα/2 ×
√
w−1i ].
Usually meta analyses are done with large samples so that the use of Zα/2, the
α/2 level of critical value from N(0,1) is justified. In standard meta analysis, the
combined estimate of the log RR, θˆ is a represented value of the individual RR’s
and so in plot of the CI’s the vertical line through θˆ as a representative value of the
individual RR’s and so the vertical line through θˆ is expected to go through all the
trials and their concomitant error bars.
If there exists heterogeneity among the treatment effects, meta analysis fails to
give any conclusive result of the pooled treatment effect [6]. So it is necessary to test
the heterogeneity whether the treatment effects for the population from which the
samples of individual studies come differ significantly. Here the null hypothesis is
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H0 : θ1 = θ2 = · · · = θk = θ against the alternative, HA: at least one of the pairs
(θi, θj) differ for i, j = 1, 2, · · · , k. An appropriate test statistic is
χ2 =
n∑
i=1
[lˆi − ln(θˆ)]× wi
Under the null hypothesis χ2 follows approximately chi-square distribution with
(k-1) degrees of freedom. The value of the test statistic measures the departure of the
individual values of the parameter from its common value in log scale. The cut off
point χ2k−1(α) at α -level based on the central chi-squared distribution with (k-1) d.f.
If χ2obs > χ
2
k−1(α), we don’t accept the null hypothesis, whereas for χ
2
obs < χ
2
k−1(α)
we don’t reject the null hypothesis.
2.2 Analytical Results
Here we perform two standard meta analyses, one for studies with homogenous treat-
ment effects and other for heterogenous treatment effects. For the first study we
consider the data from the results of treatments of infectious disease mononucleosis
(IDM) with a history of tonsillectomy (T) among seven age groups of students aged
18-24. The data are taken from Schork and Remington (2000, see Example 5; p.
218) [7]. Students diagnosed as having IDM were compared with the “control” (C)
group students who are free from the disease. The different age groups are treated
as separate studies. Result of meta analysis from the set of homogenous studies are
shown in Table 2. It presents the relative risks, weights and 95% confidence intervals
of RR for all the studies as well as the pooled estimate of the RR. The confidence
interval for the Pooled RR is constructed using the standard deviation combined by
Mantel-Haenszel [8] method.
Table 2 Standard meta analysis for homogenous studies.
age 18 19 20 21 22 23 24 Meta
Analysis
IDM 6/23 3/42 12/41 8/46 5/15 2/9 4/9
Control 17/49 26/96 34/112 48/139 45/118 29/66 36/75
RR 0.75 0.26 0.96 0.50 0.87 0.51 0.93 0.66
Weight 6.19 2.96 12.59 8.55 6.80 2.45 6.52
95% CI .34-1.65 .08-.82 .55-1.68 .26-.98 .41-1.85 .14-1.77 .43-1.99 .53-.81
The result from standard meta analysis is also represented in Figure 1. Here the
values of relative risks for the studies (age groups) varies from 0.26 for students aged
19 years to 0.96 for those aged 20. If we consider the age groups as individual studies,
we may get some misleading conclusion from the study. For the age group 19, the
result indicates a (1−0.26)×100% = 74% reduction in tonsillectomy for the treatment
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Figure 1: 95% Confidence intervals for estimated relative risk
group with respect to control group. However, for the age group 20, it shows only
4% reduction rate. For the age groups, 18, 21, 22, 23, and 24, the percentages of
reduction rates in the history of tonsillectomy for the treatment groups with respect
to control groups are 25, 50, 13, 49 and 7 respectively. This variation in the relative
risks of individual studies may be due to sampling fluctuations of the studies due to
relatively smaller sample sizes.
From the meta analysis, we get combined relative risk as 0.66. We see that the
value of the pooled relative risk lies between the 95% confidence limits of the individ-
ual CI’s for all the studies. The dotted vertical line of the graph from the estimated
value of the pooled effect passes through all the strata and their concomitant error
bars. We then carry out a test to check the heterogeneity of the trials. The observed
value of the chi-square statistic is found to be χ2 = 6.53. The critical at the 5%
significance level value for the test with 6 degrees of freedom is χ26(.05)=12.59. The
observed value of the chi square statistic is less than its critical value at the 5% sig-
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nificance level indicating that there is not enough sample evidence to reject the null
hypothesis. From the result we can conclude that there exists no significant difference
among the population relative risks for different age groups. In such a case we get a
conclusive result by combining the individual studies. We accept the common value
of the relative risk as 0.66, which corresponds to an estimated 34% reduction of the
relative risk of the IDM attributed due to tonsillectomy.
Table 3 Standard meta analysis for heterogenous studies.
Trials Diuretics Control RR Weight CI
Wesley 14/131 14/136 1.04 7.82 0.52-2.09
Flowers 21/385 17/134 0.43 10.38 0.23-0.79
Menzies 14/57 24/48 0.49 13.38 0.29-0.84
Fallis 6/38 18/40 0.35 5.85 0.16-0.79
Cuadros 12/1011 35/760 0.26 9.12 0.13-0.49
Landerman 138/1370 175/1336 0.77 87.09 0.62-0.95
Krans 15/506 20/524 0.78 8.87 0.40-1.05
Tervila 6/108 2/103 2.86 1.54 0.59-13.85
Campbill 65/153 40/102 1.08 41.59 0.80-1.47
Meta-analysis 0.71 0.62-0.82
Heterogeneous Studies:
Table 3 represents the results for another meta analysis. The data shown here
come from a meta analysis of nine randomized controlled trials investigating the use
of diuretics to prevent preeclampsia. We use the data from Thompson and Pocock
(1987, Lancet 338) [9]. For each treatment group, the proportion of patients devel-
oping preeclampsia is shown. For all the nine studies the relative risks, weights and
confidence intervals are presented in the table. The relative risk for the Cuadros
trial is 0.26 which implies a 74% reduction in the risk of preeclampsia to Diuretics
imposed group with respect to control group. Whereas, for the Tervila trial treat-
ment group shows 1.86 times more risk of the disease with respect to the control
group. Thus some of the treatments considered here shows completely opposite re-
sults. However the pooled relative risk for the meta analysis is 0.71 which indicates a
29% reduction in relative risk in diuretics group with respect to control group. The
value of the pooled relative risk is not contained in the 95% confidence limits for
the RR of the trials Cuadrons and Campbill. These two may be the outliers for the
study. From Figure 2 we see that the vertical line through the point 0.71 does not
pass through the concomitant error bars for the studies Cuadros and Campbell. To
test H0 : θ1 = θ2 = · · · = θk = θ vs HA: at least one of the pairs (θi, θj) differ for
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Figure 2: 95% Confidence intervals for relative risk
i, j = 1, 2, . . . , k, the observed χ2 value for the study is 28.81 with 8 degrees of free-
dom. The critical value is χ28(.05) = 15.07, which is less than the observed value. So
the null hypothesis is rejected and we conclude that the population relative risks for
the studies differs significantly. In this case the meta analysis to combine the individ-
ual studies in estimating the parameters is not statistically valid and fail to provide
any valid conclusive result. An alternative methodology is pursued to conduct meta
analysis when the the studies are heterogeneous with respect to the treatment effects.
3 Improved Meta Analysis
The proposed improved meta analysis uses the predicted relative risk, rather than
the estimated relative risk, in the computation of the confidence intervals and pooled
results.
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3.1 Methodology
The standard meta analysis of relative risk in Table 3 is not conclusive as there exists
heterogeneity among the studies. The vertical line through the estimated value of
combined relative risk does not pass through all the trials and their concomitant error
bars. To overcome the problem of combining treatment effects for heterogeneity set of
studies, Saleh et al. [4] introduced an improved estimate of meta analysis. They car-
ried out a test of homogeneity of individual treatment effects and combined the value
of test statistic with the treatment effects to get improved meta analysis. Combining
the test statistic and usual estimated values, there exists improved estimators in the
theory of inference. Some of such estimators are preliminary test estimator (PTE)
[10, 11], Stein type estimator (SE) and positive-rule Stein type estimator (PRSE)
[12]. On the basis of these theories, Saleh et al. [4] proposed a new estimator for
odds ratios namely predicted odds ratio (POR’s). Here the method is adopted for
meta analysis of the RR.
Steps for conducting improved meta analysis are as follows.
Performing a standard meta analysis of the set of study effects. Testing the
homogeneity of the studies and check weather the study effects differ significantly.
Get the observed value of the test statistic and combine it with treatment effects to
get the log predictive relative risks as
ln(PRR)= common ln(RR) + c (observed ln(RR) - common ln(RR)) (3.1)
where c = 1− [ν − 2]/[χ2 − value] in which ν = k − 1, the degrees of freedom of the
χ2 statistic.
We estimate 95% confidence intervals for the study effects and check whether the
value of the estimated pooled effect passes through the confidence limits of all the
trials and their concomitant error bars.
If there exists any outlier in the set of studies, we perform another meta analysis
excluding the trial from our analysis.
If there are more than one outliers then we consider the amount of diversity of
the respective study effect and the weight of the study before excluding any of them
from the final study. Finally we perform another improved meta analysis with the
rest of trials and check the results.
3.2 Analytical Results
In the second meta analysis, the observed value of χ2 is 28.81 with 8 degrees of
freedom. The value of the constant for calculating the predicted relative risk is
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Figure 3: 95% Confidence Intervals for Predicted Relative Risk for all trials
c = (1− 6/28.81) = 0.79. Using the value we get the estimated log predicted relative
risk for Wesley trial as
ln(PRR) = −0.34249+0.79(0.039221−(−0.34249)) = −0.049 and hence the PRR for
the trial becomes exp(−0.049) = 0.960 Predicted relative risks and 95% confidence
intervals for all the nine studies are shown in Table 4 and presented in Figure 3.
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Table 4 Improved meta analysis for nine studies.
Trials RR CI lower limit CI upper limit
Wesley 0.97 0.48 1.94
Flowers 0.48 0.26 0.88
Menzies 0.53 0.31 0.94
Fallis 0.41 0.18 0.94
Cuadros 0.32 0.17 0.61
Landerman 0.76 0.62 0.94
Krans 0.77 0.40 1.48
Tervila 2.15 0.44 10.34
Campbill 1.00 0.74 1.38
Meta-analysis 0.71 0.62 0.82
From Tables 4 and 5 we see that the predicted relative risks are much closer to
the pooled relative risk than the relative risks estimated by standard meta analysis.
We get a better set of estimates. However there exists two extreme values here. The
PRR for Cuadros trial is 0.32 which implies 68% reduction in the risk of preeclampsia
attributed to the use of diuretics. Whereas, the Tervila trial shows 1.13 times increase
of the risk for the diuretics user group. For rest the of the trials, the PRR’s take
values between 0.41 and 1.00.
From Figure 3 we see that the confidence intervals for the PRR’s of the trials,
Wesley, Landermad, Tervila amd Campbell, are shifted to the left and that for the
other trials shifted to the right. All the CI’s are closer to the value of the pooled esti-
mate of the PRR than relative risk for standard meta analysis. Unlike the standard
meta analysis the vertical line through the pooled PRR passes through the concomi-
tant error bar of the PRR of Campbill trial. However the confidence limits of the
PRR of Cuadros trial don’t contain value of the combined estimate. In all aspects
Cuadros trial is found to be a outlier of the set of studies. It may be due to the
clinical difference of the study from the others but the actual reason is not known to
us. We then perform the meta analysis excluding the Cuadros trial.
Table 5 Improved Meta Analysis for Eight Studies (except the study of Cuadros).
Standard Meta Analysis Improved Meta Analysis
Trials RR CI lower CI upper PRR CI lower CI upper
Wesley 1.04 0.52 2.09 0.94 0.47 1.90
Flowers 0.43 0.23 0.79 0.52 0.29 0.96
Menzies 0.49 0.29 0.84 0.57 0.34 0.98
Fallis 0.35 0.16 0.79 0.46 0.20 1.03
Landerman 0.77 0.62 0.95 0.77 0.63 0.95
Krans 0.78 0.40 1.50 0.78 0.40 1.50
Tervila 2.86 0.59 13.85 1.86 0.38 8.98
Campbill 1.08 0.80 1.47 0.97 0.71 1.31
Meta-analysis 0.78 0.67 0.90
11
Predicted Relative Risk
St
ud
y 
Re
fe
re
nc
e
0.25 0.63 1.58 3.98 10.00
Wesley
Flowers
Menzies
Fallis
Landerman
Krans
Tervila
Campbill
Summary
Relative Risk
St
ud
y 
Re
fe
re
nc
e
0.16 0.40 1.00 2.51 6.31 15.85
Wesley
Flowers
Menzies
Fallis
Landerman
Krans
Tervila
Campbill
Summary
Figure 4: 95% Confidence intervals for predicted relative risk and relative risk of eight
studies
Revised Analysis:
We again test the heterogeneity of the eight studies considered for final study.
The observed value of chi-square for the studies is 18.05 with 7 degrees of freedom.
The observed value is larger than the critical value (14.07) of chi-square at .05 level
with the same degrees freedom. There still exist heterogeneity among the studies.
The conventional meta analysis is not able to give a conclusive result and the pooled
value of the relative risk does not pass through the confidence limits of all the trials
and their concomitant error bars. We perform improved meta analysis once again.
The value of c in this case is 7−2
18.05
= 0.72.
The results of both standard and improved meta analyses from the remaining
eight studies are presented in Table 5. Figure 4 shows the graphical representation
of the two sets of study effects. Standard meta analysis of the 8 studies shows the
estimated relative risks of individual studies ranges from 0.35 to 2.86. It also reveals
the fact that there are three studies with estimated relative risks more than one.
Moreover there exists very high variability among the treatment effects. Based on
the available results, if we consider Tervila’s trial as an outlier, there still exists
heterogeneity. Fallis’ trial indicates 65% reduction in the estimated relative risk of
preeclampsia for the treatment group with respect to the control group. Whereas
for the Campbill’s trial, treatment group possesses 8% more risk than the control
group. Excluding the study of Cuadros from the analysis, we see that the predicted
relative risks of the other trials are getting closer to the value of the pooled PRR
with the exception of Tervila (with 1.86 PRR) all other PRRs lie between 0.46 and
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Figure 5: Display of estimated relative risks and predicted relative risks of eight
studies
0.97. The values of PRRs indicate a reduction in the risk of preeclampsia for the
treatment group with respect to the control group. The percentages of reduction in
the relative risks due to the treatment varies from 3 to 54. The study of Tervila
possesses relatively lower effect, and hence has a little impact on the RR of combined
study. The estimated pooled value of the predicted relative risk is 0.78. The vertical
line from this point passes through the 95% confidence limits of all the study effects
and their concomitant error bars. So it may be considered that the pooled estimate
of the effects is a representative value of all the studies.
The ray-plot in Figure 5 demonstrates how the predicted relative risks shrink
towards the pooled estimate of the relative risks. The vertical lines, here labeled
as the estimated relative risk and predicted relative risk respectively, hold the rays
emitting from the pooled value of the RR from all the studies. It is clear from the
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figure that the rays to the line of predicted RR are concentrating more towards the
pooled RR (at the centre) than those to the line of estimated RR. Thus the improved
estimates of RR’s based on the predicted RR are providing better results with respect
to the spread of the estimates.
4 Concluding remarks
The foregoing analyses show that the improved meta analysis based on the predicted
relative risk provide shorter confidence interval compared to the standard meta anal-
ysis based on estimated relative risk. Also, the new method helps shrink the limits
of the confidence intervals closer to the pooled estimate than the standard method.
Particularly the benefit of the use of the new method is evident when the effects of
the studies are heterogenous.
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